Search This Blog

Tuesday, June 2, 2026

Travere licenses BTK inhibitor civorebrutinib for rare kidney diseases from Everest for $112.5 m upfront

 

Travere Therapeutics licenses BTK inhibitor civorebrutinib for rare kidney diseases from Everest Medicines for $112.5 million upfront

  • H.C. Wainwright raised Travere Therapeutics price target to $67 from $57, reiterating Buy after civorebrutinib deal with Everest Medicines.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)